ClinicalTrials.gg
TerminatedNCT03591874oGVHDUpdated Jul 6, 2022Results posted

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

A Phase 3 interventional study of Brimonidine Tartrate and Placebos in Graft Versus Host Disease, Ocular Surface Disease and oGVHD, sponsored by Ocugen. Terminated at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-06.

Sponsored by Ocugen · Phase 3, Interventional, and Treatment

Why this study was terminated
Primary endpoint was not met.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
89th of 389
59 · median 30
Started
2018
with 14 others
Phase 3
40 of 454
2 open now
Registered
348th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 89th largest by enrollment of the 389 interventional ones that give a count, is one of 15 that started in 2018, is one of 40 in phase 3, and was the 348th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular Graft Verses Host Disease (oGVHD). Two thirds of participants will receive Brimonidine and one third will receive ophthalmic buffered saline (placebo).

Read the detailed description

Ocular GVHD (oGVHD) is a common complication that occurs in 40-60% of patients who have undergone allogeneic bone marrow transplants. Driven by inflammation, oGVHD can result in damage to the ocular surface and tear-producing glands, which over time significantly diminishes quality of life and restricts daily activities due to visual impairment.

Early studies in animals and humans indicate that Brimonidine nano-emulsion, also known as OCU300, may relieve the signs and symptoms of oGVHD. These symptoms include blurry vision, foreign body sensation, burning sensation, severe light sensitivity, chronic conjunctivitis (pink or red eye), dry eyes and eye pain.

This study will be a randomized, placebo-controlled, double-masked, multicenter phase 3 study in the United States conducted at approximately 15 centers. Upon meeting the eligibility criteria, enrolled subjects with a diagnosis of definite oGVHD will be randomly assigned in a 2:1 (test: control) fashion to receive either Brimonidine Nanoemulsion Eye Drops 0.18% investigational product (test) or ophthalmic buffered saline (placebo).

03

Conditions studied

  • Graft Versus Host Disease
  • Ocular Surface Disease
  • oGVHD
  • Ocular Graft vs Host Disease
  • Brimonidine Tartrate
  • Lubricant Eye Drops
  • Ophthalmic Solutions
  • Graft vs Host Disease

Browse trials for

Keywords

  • ogvhd
  • ocular graft vs host
  • Ocular Surface Disease
  • Ocular Graft vs Host Disease
  • Brimonidine Tartrate
  • Lubricant Eye Drops
  • Ophthalmic Solutions
  • Graft vs Host Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ≥ 18 years of age
  • Diagnosis of definite oGVHD using the International Chronic Ocular Consensus Group Revised Diagnostic criteria in at least one eye.
  • Ocular Discomfort score ≥ 3
  • Validated Bulbar Redness score ≥ 40 in both eyes
  • Subjects who are capable and willing to provide and follow study instructions
  • Intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in each eye
  • Women who are not pregnant or lactating or or have undergone a sterilization procedure

Exclusion criteria

Exclusion Criteria:

  • Allergic to brimonidine or any similar products, or of brimonidine
  • Currently receiving any brimonidine or other treatment for glaucoma
  • Receiving or have received any drug or device within 30 days of screening
  • Current use of contact lenses 14 days prior to screening
  • Active ocular infection or ocular allergies
  • Any history of eyelid surgery or ocular surgery within the past 3 months
  • Corneal epithelial defect larger than 1 mm (squared) in either eye
  • Received -containing eye drops within 14 days prior to screening or planned use during the study
  • Any change in corticosteroid-containing eye drops, systemic corticosteroids/immunosuppressives, topical ocular antibiotics, cyclosporine ophthalmic emulsion 0.05% (Restasis®), cyclosporine ophthalmic solution 0.09% (Cequa®) or lifitegrast ophthalmic solution 5% (Xiidra®), or autologous serum tears within 30 days prior to screening or planned change during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    OCU-300

    Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.

    Drug: Brimonidine Tartrate

  • Placebo comparator
    Placebos

    Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.

    Drug: Placebos

Interventions

  • Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.

    Also known as: OCU-300

  • DrugPlacebos

    Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.

    Also known as: Placebo (For Brimonidine Tartrate)

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 84 in Validated Bulbar Redness (VBR) Score

    The VBR consists of a set of ten images illustrating different degrees of ocular redness, ranging from normal to severe, and each image is assigned a value from 10 (least redness) to 100 (most redness). The bulbar conjunctival injection of the participant's eye (nasal and temporal) was examined via slit-lamp examination and compared to the reference images in the VBR and graded accordingly.

    Time frame: Baseline, Day 84

  2. Change From Baseline to Day 84 in Ocular Discomfort Visual Analog Scale (VAS) Score

    Participants were asked to rate their worst ocular pain/discomfort in the preceding 24 hours using a 10-point scale ranging from "None" (score=0) to "Unbearable/Excruciating" (score=10).

    Time frame: Baseline, Day 84

Secondary outcomes

  1. Change From Baseline to Day 84 in Symptom Assessment iN Dry Eye (SANDE) Questionnaire Scores

    The SANDE questionnaire is a short VAS assessment that quantifies both severity and frequency of current dry eye symptoms. The SANDE is comprised of two questions, and each question employs a 100-mm horizontal linear VAS. The measurement of symptom frequency ranges from "rarely" to "all of the time", and the symptom severity from "very mild" to "very severe". Data collected from the SANDE questionnaire was calculated by multiplying the frequency score by the severity score and obtaining the square root. The result is the Overall SANDE score which ranges from 0 to 100, with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

    Time frame: Baseline, Day 84

07

Results

Posted Jul 6, 2022

Participant flow

Participant flow — Overall Study
MilestoneOCU-300Placebo
Started4019
Received at least 1 study treatment2916
Completed2112
Not completed197
Withdrew: Adverse event40
Withdrew: Withdrawal by subject21
Withdrew: Investigator withdrawal of subject10
Withdrew: On study at time of study termination126

Outcome measures

PrimaryChange From Baseline to Day 84 in Validated Bulbar Redness (VBR) Score

The VBR consists of a set of ten images illustrating different degrees of ocular redness, ranging from normal to severe, and each image is assigned a value from 10 (least redness) to 100 (most redness). The bulbar conjunctival injection of the participant's eye (nasal and temporal) was examined via slit-lamp examination and compared to the reference images in the VBR and graded accordingly.

Time frame:
Baseline, Day 84
Reported as:
Mean · score on a scale
Change From Baseline to Day 84 in Validated Bulbar Redness (VBR) Score
score on a scaleOCU-300Placebo
Baseline52.23 ± 9.23851.92 ± 11.821
Day 8434.88 ± 14.65237.71 ± 19.378
Change from Baseline to Day 84-17.62 ± 14.086-13.96 ± 14.161
PrimaryChange From Baseline to Day 84 in Ocular Discomfort Visual Analog Scale (VAS) Score

Participants were asked to rate their worst ocular pain/discomfort in the preceding 24 hours using a 10-point scale ranging from "None" (score=0) to "Unbearable/Excruciating" (score=10).

Time frame:
Baseline, Day 84
Reported as:
Mean · score on a scale
Change From Baseline to Day 84 in Ocular Discomfort Visual Analog Scale (VAS) Score
score on a scaleOCU-300Placebo
Baseline6.2 ± 1.776.5 ± 1.85
Day 844.8 ± 2.864.1 ± 3.67
Change from Baseline to Day 84-1.8 ± 3.33-2.6 ± 2.69
SecondaryChange From Baseline to Day 84 in Symptom Assessment iN Dry Eye (SANDE) Questionnaire Scores

The SANDE questionnaire is a short VAS assessment that quantifies both severity and frequency of current dry eye symptoms. The SANDE is comprised of two questions, and each question employs a 100-mm horizontal linear VAS. The measurement of symptom frequency ranges from "rarely" to "all of the time", and the symptom severity from "very mild" to "very severe". Data collected from the SANDE questionnaire was calculated by multiplying the frequency score by the severity score and obtaining the square root. The result is the Overall SANDE score which ranges from 0 to 100, with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

Time frame:
Baseline, Day 84
Reported as:
Mean · score on a scale
Change From Baseline to Day 84 in Symptom Assessment iN Dry Eye (SANDE) Questionnaire Scores
score on a scaleOCU-300Placebo
Baseline74.4 ± 18.9769.1 ± 21.90
Day 8450.5 ± 24.0544.1 ± 36.43
Change from Baseline to Day 84-26.5 ± 22.24-26.6 ± 27.50

Adverse events

Collected over Day 1 (post-dose) up to 84 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OCU-3000/29 (0%)2/29 (6.9%)1/29 (3.4%)
Placebo0/16 (0%)1/16 (6.3%)4/16 (25%)
Most frequent serious events
Most frequent serious events
EventOCU-300Placebo
Gastrointestinal infectionInfections and infestations0/291/16
PneumoniaInfections and infestations0/291/16
DyspnoeaRespiratory, thoracic and mediastinal disorders1/290/16
HypoxiaRespiratory, thoracic and mediastinal disorders1/290/16
Coronary artery diseaseCardiac disorders1/290/16
FallInjury, poisoning and procedural complications1/290/16
Most frequent other events
Most frequent other events
EventOCU-300Placebo
InfluenzaInfections and infestations1/291/16
PneumoniaInfections and infestations0/291/16
CoughRespiratory, thoracic and mediastinal disorders0/291/16
Dry mouthGastrointestinal disorders0/291/16

Baseline characteristics

The safety set includes all participants who signed informed consent forms, were randomized into the study, and took at least one dose of study drug.

Age, Continuous
Age, Continuous(years)OCU-300PlaceboTotal
Mean54.5 ± 13.9162.4 ± 7.7457.3 ± 12.57
Sex: Female, Male
Sex: Female, Male(Participants)OCU-300PlaceboTotal
Female8614
Male211031
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OCU-300PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino291645
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OCU-300PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White281543
More than one race000
Unknown or Not Reported101
08

Study locations

13 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • Byers Eye Institute at Stanford University
    Palo Alto, California 94303, United States
  • Emory Eye Center
    Atlanta, Georgia 30322, United States
  • University of Kansas Medical Center
    Prairie Village, Kansas 66208, United States
  • University of Michigan, Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • Duke University Medical Center
    Durham, North Carolina 27708, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • OHSU Casey Eye Institute | Cornea Division
    Portland, Oregon 97239, United States
  • University of Penn Scheie Eye Institute,
    Philadelphia, Pennsylvania 19104, United States
  • Univeristy of Pittsburgh Medical Center Eye Center
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Wisconsin Dept. of Ophthalmology and Visual Sciences
    Madison, Wisconsin 53705, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — There is no current plan to share participant data with other researchers.

Supporting information: Clinical study report

Time frame: A clinical Study Report will be submitted once the study data has been analyzed.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Apr 2020, 16 months.

Results were first posted in Jul 2022, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2018
First posted
Jul 19, 2018
StartActual
Dec 23, 2018
Primary completionActual
Apr 30, 2020
CompletionActual
Apr 30, 2020
Results first posted
Jul 6, 2022
Last update
Jul 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03591874
Lead sponsor
Ocugen
Responsible party
Sponsor
First posted
Jul 19, 2018
Start date
Dec 23, 2018
Primary completion
Apr 30, 2020
Completion
Apr 30, 2020
Results posted
Jul 6, 2022
Last update
Jul 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion